VON WILLEBRAND FACTOR IN ECMO: A DYNAMIC MODULATOR OF HEMORRHAGE AND THROMBOSIS.

Area of Science:

• Biochemistry
• Hematology
• Medical Engineering

Background:

• Von Willebrand factor (vWF) is crucial for hemostasis, regulating platelet activation and factor VIII stability.
• ADAMTS13 protease cleaves vWF, but its efficiency decreases under high shear stress, such as in ECMO circuits.
• vWF self-association and inflammatory mediators also influence its thrombotic potential during ECMO.

Purpose of the Study:

• To review the complex, biphasic changes in vWF function during ECMO support.
• To highlight the inadequacy of current anticoagulation and monitoring strategies for ECMO patients.
• To propose a temporal management framework for maintaining vWF-ADAMTS13 homeostasis.

Main Methods:

• Synthesis of mechanistic insights from shear-stress models.
• Analysis of clinical outcome studies related to ECMO and vWF.
• Review of emerging monitoring technologies for vWF and ADAMTS13.

Main Results:

• ECMO induces a biphasic vWF response: a prothrombotic phase followed by a hemorrhagic phase.
• Acquired von Willebrand syndrome and platelet dysfunction can occur simultaneously.
• A paradoxical surge in endothelial vWF post-ECMO increases thrombosis risk despite anticoagulation.

Conclusions:

• Current anticoagulation strategies are inadequate for managing ECMO-associated hemostatic complications.
• Pulsatile flow modulation and vWF multimer monitoring show potential but require further validation.
• A temporal management framework is needed to optimize vWF-ADAMTS13 homeostasis throughout ECMO treatment.